ProQR Therapeutics N.V. (PRQR) Institutional Ownership

Ownership Summary

ProQR Therapeutics N.V. (NASDAQ:PRQR) has 63 institutional investors with active 13F positions as of December 2025.

• Their combined ownership stood at 35.1% of outstanding shares in December 2025, down from 35.6% in September 2025.
• They increased total shares held in PRQR by 5.28% quarter over quarter, and investors in ProQR Therapeutics decreased 16.0% from a year ago.
• Of these 63 funds, 32 grew their exposure to ProQR Therapeutics, 12 cut back, and 19 maintained positions.
• In total, institutional investors held 37.02Mn shares in ProQR Therapeutics as of December 2025, up by 1.86Mn shares quarter on quarter, and down 8.03Mn shares year over year.
• As of December 31, 2025, the biggest holder of ProQR Therapeutics is ADAGE CAPITAL PARTNERS GP, L.L.C. at 6.25Mn shares, representing 5.94% of shares outstanding.
• The most significant purchases of PRQR for the quarter ending December 2025 came from UBS Group AG (703.11K), Aberdeen Group plc (651.85K), NOMURA ASSET MANAGEMENT INTERNATIONAL INC. (620.0K), Ikarian Capital, LLC (600.0K), TWO SIGMA INVESTMENTS, LP (422.08K).
• The largest sales of PRQR for the quarter ending December 2025 came from Morgan Stanley (1.53Mn), Affinity Asset Advisors, LLC (1.15Mn), Kynam Capital Management, LP (83.14K), Royal Bank Of Canada (81.9K), ArrowMark Colorado Holdings LLC (81.51K).
• Business Quant data shows the 10 biggest positions in ProQR Therapeutics as of December 2025 are held by ADAGE CAPITAL PARTNERS GP, L.L.C. (6.25Mn), Privium Fund Management B.V. (5.36Mn), Aberdeen Group plc (2.95Mn), Affinity Asset Advisors, LLC (2.45Mn), Sio Capital Management, LLC (2.16Mn), DAFNA Capital Management LLC (1.57Mn), Kynam Capital Management, LP (1.57Mn), Ikarian Capital, LLC (1.49Mn), Morgan Stanley (1.37Mn), PLATINUM INVESTMENT MANAGEMENT LTD (1.24Mn).